GFM
EWTX icon

GF Fund Management’s Edgewise Therapeutics EWTX Stock Holding History

GF Fund Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.3K Sell
2,272
-106
-4% -$3.65K ﹤0.01% 339
2026
Q1 		$74.9K Buy
2,378
+299
+14% +$8.62K ﹤0.01% 363
2025
Q4 		$51.6K Sell
2,079
-187
-8% -$3.75K ﹤0.01% 404
2025
Q3 		$36.8K Sell
2,266
-158
-7% -$2.24K ﹤0.01% 425
2025
Q2 		$31.8K Hold
2,424
– – ﹤0.01% 453
2025
Q1 		$53.3K Buy
2,424
+436
+22% +$11.4K ﹤0.01% 415
2024
Q4 		$53.1K Buy
+1,988
New +$63.3K ﹤0.01% 386

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GF Fund Management's EWTX Position: Q2 2026 in Review

GF Fund Management reduced its Edgewise Therapeutics (EWTX) stake by 4.5% in Q2 2026, selling an estimated $3.65K and leaving 2,272 shares worth $92.3K. The position accounts for ﹤0.01% of the portfolio, ranked #339.

GF Fund Management first reported a position in EWTX in Q4 2024 and has held it in 7 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • GF Fund Management held 2,272 shares of Edgewise Therapeutics worth $92.3K as of Q2 2026.
  • GF Fund Management sold 106 Edgewise Therapeutics shares in Q2 2026, an estimated $3.65K.
  • Edgewise Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #339 holding.
  • GF Fund Management first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.